LUC00139I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00139I2 LUC00139I2 LU00139C LUC00139C LUC00139I2 LU C00139 I2 LUC00139 I2 LU C00139I2 LU 00139 C LU00139 C LU 00139C LU C00139 C LUC00139 C LU C00139C LU C00139 I2 LUC00139 I2 LU C00139I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- sub
- atoms
- nitrogen
- formula
- fused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30919601P | 2001-07-31 | 2001-07-31 | |
US38215502P | 2002-05-20 | 2002-05-20 | |
PCT/US2002/024212 WO2003011277A2 (fr) | 2001-07-31 | 2002-07-30 | Methodes de mobilisation de cellules souches/embryonnaires |
EP02750370A EP1411918B1 (fr) | 2001-07-31 | 2002-07-30 | Methodes de mobilisation de cellules souches/embryonnaires |
Publications (2)
Publication Number | Publication Date |
---|---|
LUC00139I1 LUC00139I1 (fr) | 2019-11-27 |
LUC00139I2 true LUC00139I2 (fr) | 2021-02-10 |
Family
ID=26976666
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92033C LU92033I2 (fr) | 2001-07-31 | 2012-06-27 | Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) |
LU00139C LUC00139I2 (fr) | 2001-07-31 | 2019-11-26 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92033C LU92033I2 (fr) | 2001-07-31 | 2012-06-27 | Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) |
Country Status (29)
Country | Link |
---|---|
US (9) | US6987102B2 (fr) |
EP (3) | EP1411918B1 (fr) |
JP (2) | JP5137288B2 (fr) |
KR (2) | KR100996378B1 (fr) |
CN (2) | CN102302493B (fr) |
AT (1) | ATE538785T1 (fr) |
AU (1) | AU2002318927B2 (fr) |
BE (1) | BE2019C544I2 (fr) |
BR (1) | BRPI0211570B8 (fr) |
CA (1) | CA2455559C (fr) |
CY (4) | CY1112633T1 (fr) |
DK (2) | DK1411918T3 (fr) |
ES (2) | ES2742730T3 (fr) |
FR (2) | FR12C0042I1 (fr) |
HK (1) | HK1063005A1 (fr) |
HU (1) | HUP0402360A2 (fr) |
IL (2) | IL159312A0 (fr) |
LT (2) | LT2371361T (fr) |
LU (2) | LU92033I2 (fr) |
MX (1) | MXPA04000982A (fr) |
NL (2) | NL300537I2 (fr) |
NO (4) | NO336989B1 (fr) |
NZ (1) | NZ530169A (fr) |
PL (1) | PL364673A1 (fr) |
PT (2) | PT1411918E (fr) |
RU (1) | RU2309741C2 (fr) |
SI (2) | SI1411918T1 (fr) |
WO (1) | WO2003011277A2 (fr) |
ZA (1) | ZA200400658B (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100996378B1 (ko) | 2001-07-31 | 2010-11-25 | 아노르메드 인코포레이티드 | 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물 |
US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
IL161784A0 (en) | 2001-12-21 | 2005-11-20 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
KR101160698B1 (ko) * | 2003-06-27 | 2012-06-28 | 아사히 가세이 가부시키가이샤 | 세포 분화 억제제, 이것을 이용하는 세포 배양 방법, 배양 배지 및 배양된 세포주 |
WO2005002522A2 (fr) * | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions et methodes pour traiter une ischemie tissulaire |
US20050069553A1 (en) | 2003-08-13 | 2005-03-31 | Yi Zheng | Chimeric peptides for the regulation of GTPases |
EP1656156A2 (fr) | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Mobilisation de cellules hematopoietques |
IL158868A0 (en) * | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
WO2005103721A1 (fr) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4) |
EP1796716A4 (fr) * | 2004-08-13 | 2010-09-08 | Anormed Inc | Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches |
US8182806B2 (en) * | 2004-09-07 | 2012-05-22 | Johnson Lanny L | Synovial villi for use with tissue engineering |
US7785582B2 (en) * | 2004-09-07 | 2010-08-31 | Johnson Lanny L | Use of synovium and omentum for tissue engineering |
JP2008519052A (ja) | 2004-11-05 | 2008-06-05 | ザ ジェネラル ホスピタル コーポレイション | 薬剤によるヒト遊走性細胞の合目的的挙動 |
ES2421447T3 (es) | 2005-06-13 | 2013-09-02 | Cleveland Biolabs Inc | Métodos para proteger frente a apoptosis usando lipopéptidos |
CN101365336B (zh) * | 2005-08-19 | 2013-05-29 | 健赞股份有限公司 | 增强化疗的方法 |
EP2267030A1 (fr) * | 2005-08-25 | 2010-12-29 | Repair Technologies, Inc. | Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus |
US7927630B2 (en) * | 2005-09-12 | 2011-04-19 | Johnson Lanny L | Use of autologous sediment from fluid aspirates as vehicles for drug delivery |
US8518349B2 (en) | 2005-09-12 | 2013-08-27 | Lanny Johnson | Use of autologous sediment from fluid aspirates as vehicles for drug delivery |
US20070116680A1 (en) * | 2005-11-18 | 2007-05-24 | Rensselaer Polytechnic Institute | Stem cells within gel microenvironments |
CN101389329A (zh) * | 2006-02-24 | 2009-03-18 | 健赞股份有限公司 | 增加血流和/或促进组织再生的方法 |
WO2007108689A2 (fr) * | 2006-03-21 | 2007-09-27 | Stichting Skeletal Tissue Engineering | Nouveau procede d'induction de la differenciation de cellules souches et progenitrices |
EP2056853A1 (fr) * | 2006-08-07 | 2009-05-13 | Genzyme Corporation | Thérapie combinée |
US7883698B2 (en) * | 2007-01-17 | 2011-02-08 | Maria Michejda | Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use |
WO2010025416A1 (fr) * | 2008-08-29 | 2010-03-04 | Genzyme Corporation | Antagonistes du cxcr4 pour des lésions rénales |
EP2493295A4 (fr) * | 2009-10-28 | 2013-05-08 | Ford Henry Health System | Méthodes d'atténuation des lésions causées par une irradiation |
CN101716167B (zh) * | 2009-12-08 | 2011-12-28 | 中国人民解放军军事医学科学院野战输血研究所 | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US20150030561A1 (en) | 2011-05-16 | 2015-01-29 | Genzyme Corp. | Use of CXCR4 Antagonists |
WO2014152629A1 (fr) * | 2013-03-15 | 2014-09-25 | Miller Leonard B | Traitement combiné pour améliorer la cicatrisation de tissu mou, la cicatrisation de greffe de tissu adipeux, la cicatrisation osseuse endochondrale et l'ostéointégration |
US9988973B2 (en) | 2015-01-06 | 2018-06-05 | Hamilton Sundstrand Corporation | Water injector for aviation cooling system |
CN108348606A (zh) | 2015-09-18 | 2018-07-31 | 综合医院公司以麻省总医院名义经营 | 用于治疗癌症的抗趋除剂的局部递送 |
US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
EP3389634B1 (fr) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Méthodes de traitement du cancer |
WO2017106630A1 (fr) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polymères polyacétal, conjugués, particules et utilisations associées |
WO2017112894A1 (fr) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Méthodes pour le traitement d'une maladie immunodéficiente |
CA3019394A1 (fr) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methodes de traitement du cancer |
WO2017216373A1 (fr) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron |
WO2017223229A1 (fr) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Inhibiteurs de cxcr4 et leurs utilisations |
CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
EP3808748A1 (fr) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Piperidines substutues comme inhibiteurs de cxcr4 |
WO2018049118A1 (fr) | 2016-09-09 | 2018-03-15 | The General Hospital Corporation | Protéine hsp hybride avec un agent anti-chimiorépulsif pour le traitement du cancer |
US11453706B2 (en) | 2016-09-09 | 2022-09-27 | The General Hospital Corporation | HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease |
WO2018049120A1 (fr) | 2016-09-09 | 2018-03-15 | The General Hospital Corporation | Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer |
WO2018106738A1 (fr) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations |
KR20200096942A (ko) * | 2017-12-06 | 2020-08-14 | 마젠타 테라퓨틱스 인코포레이티드 | 조혈 줄기 및 자손 세포의 동원을 위한 투여 요법 |
US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
TWI818938B (zh) * | 2017-12-19 | 2023-10-21 | 南韓商Gpcr醫療公司 | Gpcr異聚體抑制劑及其用途 |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
WO2021224633A1 (fr) | 2020-05-06 | 2021-11-11 | Orchard Therapeutics (Europe) Limited | Traitement pour les maladies neurodégénératives |
WO2023056444A1 (fr) | 2021-10-01 | 2023-04-06 | Janssen Pharmaceutica N.V. | Procédés d'augmentation de la production de cellules progénitrices |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US562476A (en) * | 1896-06-23 | Combined fence-wire reel and straightener | ||
US4111199A (en) * | 1977-03-31 | 1978-09-05 | Isaac Djerassi | Method of collecting transfusable granulocytes by gravity leukopheresis |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
DE3728525A1 (de) | 1987-08-24 | 1989-03-16 | Schering Ag | Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel |
FR2644453A1 (fr) | 1989-03-20 | 1990-09-21 | Centre Nat Rech Scient | Procede de preparation de tetramines cycliques monofonctionnalisees |
EP0497926B1 (fr) | 1989-10-23 | 1998-06-03 | Nycomed Salutar, Inc. | Agents chelateurs metalliques multi-sites |
US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
FR2672051B1 (fr) | 1991-01-24 | 1993-05-21 | Guerbet Sa | Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique. |
GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
EP0670735B1 (fr) | 1992-11-13 | 1997-04-02 | Board Of Regents Of The University Of Washington | Peripherisation de cellules souches hematopoietiques |
GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
JPH08127539A (ja) * | 1994-10-31 | 1996-05-21 | Ajinomoto Co Inc | ヒトil−11を含有する末梢血幹細胞増加剤 |
US5612478A (en) | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
US5606053A (en) | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
JPH0952824A (ja) * | 1995-06-05 | 1997-02-25 | Nippon Kayaku Co Ltd | 末梢血液中の造血幹細胞数を増加するための薬剤 |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US5811544A (en) * | 1995-08-28 | 1998-09-22 | Johnson Matthey Plc | Process for preparing 1,4,8,11-tetraazacyclotetradecane |
CA2305787A1 (fr) * | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Traitement antagoniste cxcr4 de cellules hematopoietiques |
DK1068357T3 (da) * | 1998-03-30 | 2011-12-12 | Northwest Biotherapeutics Inc | Terapeutiske og diagnostiske anvendelser baseret på CXCR-4-genets rolle i tumorgenese |
AU4696899A (en) | 1998-06-19 | 2000-01-05 | General Hospital Corporation, The | Modulating platelet function |
CA2244554A1 (fr) * | 1998-07-30 | 2000-01-30 | Vasogen Inc. | Inhibition d'une greffe par rapport a la maladie d'un hote |
IL142094A0 (en) * | 1998-09-29 | 2002-03-10 | Gamida Cell Ltd | Methods of controlling proliferation and differentiation of stem and progenitor cells |
ATE315390T1 (de) * | 1998-11-17 | 2006-02-15 | Smithkline Beecham Corp | Zyklische polyamine zur behandlung der thrombozytopenie |
EP1016413A1 (fr) * | 1998-12-30 | 2000-07-05 | Applied Research Systems ARS Holding N.V. | Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes |
US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
AU775123B2 (en) | 1999-03-24 | 2004-07-15 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
WO2000066112A1 (fr) * | 1999-05-03 | 2000-11-09 | Smithkline Beecham Corporation | Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine |
WO2001044229A1 (fr) | 1999-12-17 | 2001-06-21 | Anormed Inc. | Recepteur de chemokine liant des composes heterocycliques |
AU5811001A (en) | 2000-05-09 | 2001-11-20 | Univ British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
WO2001094420A1 (fr) * | 2000-06-05 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique |
MXPA03002325A (es) | 2000-09-15 | 2003-06-24 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina. |
CA2419224A1 (fr) | 2000-09-15 | 2002-03-21 | Anormed Inc. | Composes heterocycliques se liant avec les recepteurs de chimiokines |
PT1317451E (pt) | 2000-09-15 | 2006-12-29 | Anormed Inc | Compostos heterocíclicos que se ligam a receptores de quimioquinas |
PL359292A1 (en) | 2000-09-29 | 2004-08-23 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
CA2431611A1 (fr) | 2001-01-23 | 2002-08-01 | P&G-Clairol, Inc. | Intermediaires primaires pour coloration capillaire oxydante |
KR100996378B1 (ko) | 2001-07-31 | 2010-11-25 | 아노르메드 인코포레이티드 | 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물 |
US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
IL161784A0 (en) | 2001-12-21 | 2005-11-20 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
DE102014206089B4 (de) | 2014-03-31 | 2018-01-18 | BSH Hausgeräte GmbH | Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal |
-
2002
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko active IP Right Grant
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 EP EP02750370A patent/EP1411918B1/fr not_active Revoked
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/fr active Search and Examination
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/fr not_active Expired - Lifetime
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 CA CA2455559A patent/CA2455559C/fr not_active Expired - Lifetime
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Application Discontinuation
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/fr not_active Withdrawn
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 BR BRPI0211570 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
-
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
-
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
- 2004-06-18 HK HK04104446.8A patent/HK1063005A1/xx not_active IP Right Cessation
-
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
-
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
-
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en active Active
-
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
-
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
-
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I1/el unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
-
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
-
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
-
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
-
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
-
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
-
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I1/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
-
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LUC00139I2 (fr) | ||
AP1497A (en) | Methods and compositions to enhance white blood cell count. | |
HUP0004259A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények | |
KR920012082A (ko) | Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물 | |
ES2164164T3 (es) | Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa. | |
MA27576A1 (fr) | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EA200501148A1 (ru) | Пиридилоксиметильные и бензизоксазольные азабициклические производные | |
WO1994019343A3 (fr) | Nouvelle application des composes bis-heterocycliques et les compositions pharmaceutiques en tant qu'agents anti-inflammatoires | |
ATE46511T1 (de) | Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel. | |
WO1999023092A3 (fr) | 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine | |
EP1142883A4 (fr) | Nouveaux composes heterocycliques et compositions de medicaments les renfermant | |
AR026222A1 (es) | Compuestos derivados de acido antranilico | |
OA09239A (fr) | "Nouveaux céphèmes et procédés pour leur préparation". | |
WO2007106063A3 (fr) | Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu | |
EA200000527A2 (ru) | Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
EP1057829A4 (fr) | Dérivés de la pyrimidine condensés et compositions pharmaceutiques les contenant | |
ES8605524A1 (es) | Procedimiento para preparar tieno- y furo-(2,3-c)-pirroles |